Dr. Ronald M. Pucillo, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 441
Licensed in Texas since 1982, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: New York Medical College
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license G2207 (first issued 1982; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Memorial Hermann Katy Hospital Katy, TX
Medical groups
- Privia Medical Group Gulf Coast PLLC (534 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 441
- Services billed
- 9,184
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 1,400 | 12 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,076 | 99 |
| Test for allergy using allergenic extract | 1,050 | 15 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 747 | 99 |
| Professional service for multiple injections of allergen | 431 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 319 | 171 |
| Blood test, comprehensive group of blood chemicals | 305 | 199 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 289 | 192 |
| Blood test, lipids (cholesterol and triglycerides) | 281 | 191 |
| Blood test, thyroid stimulating hormone (tsh) | 236 | 151 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Sugar Land, TX | 257 |
| Levothyroxine Sodium Other prescribers in Sugar Land, TX | 176 |
| Atorvastatin Calcium Other prescribers in Sugar Land, TX | 155 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Sugar Land, TX | 154 |
| Amlodipine Besylate Other prescribers in Sugar Land, TX | 125 |
| Ezetimibe Other prescribers in Sugar Land, TX | 104 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Sugar Land, TX | 95 |
| Metformin Hcl Other prescribers in Sugar Land, TX | 94 |
| Escitalopram Oxalate Other prescribers in Sugar Land, TX | 84 |
| Zolpidem Tartrate Other prescribers in Sugar Land, TX | 81 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 98 payments worth $1,748 in total to this clinician.
| Renalytix Ai, Inc. | $261 |
|---|---|
| AbbVie Inc. | $232 |
| Avvisto Therapeutics, LLC | $204 |
| Axsome Therapeutics, Inc. | $110 |
| Novo Nordisk Inc | $101 |
| Pfizer Inc. | $87.95 |
| AstraZeneca Pharmaceuticals LP | $78.80 |
| Exact Sciences Corporation | $76.59 |
| Food and Beverage | $1,731 |
|---|---|
| Entertainment | $16.81 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Optos, Inc. Feb 17, 2025 | Entertainment NFC-700; PANORAMIC OPHTHALMOSCOPE; OCT OPHTHALMOSCOPE · OPHTHALMOLOGY · in-kind | $16.81 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $698,469 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
ModernaTX, Inc. · Completed · NCT06060457 - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - An interventional efficacy and safety phase 3 doubleblind 2ARM study to investigate orally administered ibuzatrelvir compared with placebo in nonhospitalized symptomatic adult and adolescent participants with COVID19 …
Pfizer Inc. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc. · Completed · NCT05827978 - An interventional phase 23 adaptive multicenter randomized doubleblind study to investigate efficacy and safety of oral sisunatovir compared with placebo in nonhospitalized symptomatic adults with respiratory syncytia…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.